A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
Biological tests including the monkey neurovirulence test performed on recombinants between the virulent Mahoney and attenuated Sabin 1 strains of type 1 poliovirus indicated that the genome region encoding mainly the viral capsid proteins had little correlation with the neurovirulence or attenuation phenotype of the virus. The results suggested that new vaccine strains of type 2 and type 3 polioviruses may be constructed in vitro by replacing the sequence encoding the antigenic determinants in viral capsid proteins of the Sabin 1 genome by the corresponding sequences of the type 2 and type 3 genome, respectively. Accordingly, we constructed recombinants between the Sabin 1 and Sabin 3 strains of poliovirus in which genome sequences of the Sabin 1 strain encoding most or all capsid proteins were replaced by the corresponding genome sequences of the Sabin 3 strain. One of the recombinant viruses thus constructed was fully viable and showed antigenicity and immunogenicity identical to those of type 3 poliovirus. The monkey neurovirulence tests and in vitro phenotypic marker tests (temperature sensitivity of growth, sodium bicarbonate concentration dependency of growth under agar overlay, and size of plaque) were performed on the recombinant virus. The stability of the virus in regard to the temperature sensitivity phenotype was also tested. The results suggested that the recombinant virus is a possible candidate for a new type 3 poliovirus vaccine strain.
Kohara
M
M
Department of Microbiology, Faculty of Medicine, University of Tokyo, Japan.
Abe
S
S
Komatsu
T
T
Tago
K
K
Arita
M
M
Nomoto
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis; D000941:Antigens; D000956:Antigens, Viral / Q000235:genetics; D002213:Capsid / Q000235:genetics / Q000276:immunology; D000882:Haplorhini; D009474:Neurons / Q000382:microbiology; D009500:Neutralization Tests; D017955:Poliovirus / Q000235:genetics* / Q000254:growth & development / Q000276:immunology / Q000472:pathogenicity; D011055:Poliovirus Vaccine, Oral / Q000235:genetics*; D011995:Recombination, Genetic; D014613:Vaccines, Attenuated / Q000235:genetics; D014614:Vaccines, Synthetic
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000941:Antigens; D000956:Antigens, Viral; D011055:Poliovirus Vaccine, Oral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic